ArticleEmerging microbes & infections2019
Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model.
Article in Emerging microbes & infections, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Longitudinal assessment of functional antibodies to a novel influenza virus strain across age groups.PLoS pathogens · 2026Article
- Human monoclonal antibodies that target clade 2.3.4.4b H5N1 hemagglutinin.Nature communications · 2025Article
- Epidemiology and biological characteristics of influenza A (H4N6) viruses from wild birds.Emerging microbes & infections · 2024Article
- Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses.Journal of virology · 2023Article
- Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice.Science advances · 2023Article
- Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination.Journal of virology · 2023Article
- Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses.Frontiers in bioengineering and biotechnology · 2023Article
- Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Monoclonal antibodies targeting the influenza virus N6 neuraminidase.Frontiers in immunology · 2022Article
- Article
- Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections.Viruses · 2021Review
- An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening.Current protocols in microbiology · 2020Article
- A serological assay to detect SARS-CoV-2 seroconversion in humans.medRxiv : the preprint server for health sciences · 2020Article
- Review
- Monoclonal Antibodies with Neutralizing Activity and Fc-Effector Functions against the Machupo Virus Glycoprotein.Journal of virology · 2020Article
- Generation of neutralizing and non-neutralizing monoclonal antibodies against H7N9 influenza virus.Emerging microbes & infections · 2020Article
- Enhanced Potency of a Broad H7N9-Neutralizing Antibody HNIgGA6 Through Structure-Based Design.Frontiers in microbiology · 2020Article
- Cross-Reactive Antibodies Binding to the Influenza Virus Subtype H11 Hemagglutinin.Pathogens (Basel, Switzerland) · 2019Article
- Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus.Viruses · 2019Review
- A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains.NPJ vaccines · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Influenza viruses of the H4 subtype are widespread in wild birds, circulate in domestic poultry, readily infect mammals, and tolerate the insertion of a polybasic cleavage site. In addition, serological evidence suggests that humans working with poultry are exposed to these viruses. While H4 viruses are not of immediate pandemic concern, there is a lack of knowledge regarding their antigenicity. In order to study viruses of the H4 subtype, we generated and characterized a panel of antibodies that bind a wide variety of H4 hemagglutinins from avian and swine isolates of both the Eurasian and North American lineage. We further characterized these antibodies using novel recombinant H4N6 viruses that were found to be lethal in DBA/2J mice. Non-neutralizing antibodies, which had activity in an antibody dependent cell-mediated cytotoxicity reporter assay in vitro, protected mice against challenge in vivo, highlighting the importance of effector functions. Our data suggest a high degree of antigenic conservation of the H4 hemagglutinin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.